Statements of Operations
Ended March 31,
Research and development costs
General and administrative expenses
Depreciation and amortization
Total operating expenses
Nonoperating income (expense):
Warrant issuance and modification expense
Gain (loss) from change in fair value adjustment of warrant obligations
Total nonoperating income (expense)
Net loss attributable to common shareholders
Net loss per share - basic and diluted
Weighted average common shares outstanding - basic and diluted
Subscribe to our Free Newsletters!
High blood pressure or hypertension is a chronic condition, which usually lasts a lifetime once it ...
This cancer affects men over the age of 50 years and screening with rectal examination and PSA can ...
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...View All